Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints
Crossref DOI link: https://doi.org/10.1186/s13023-014-0195-4
Published Print: 2015
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kakkis, Emil D
O’Donovan, Mary
Cox, Gerald
Hayes, Mark
Goodsaid, Federico
Tandon, PK
Furlong, Pat
Boynton, Susan
Bozic, Mladen
Orfali, May
Thornton, Mark
License valid from 2015-01-01